Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib

Completed · Phase 2

Conditions studied: Carcinoma, Non-Small-Cell Lung

In brief

The purpose of this study is to determine the best confirmed response rate of daily administration of the multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR and VEGFR2) XL647 in subjects with NSCLC who have progressed after responding to treatment with either erlotinib or gefitinib.

Key facts

Study ID

NCT00522145

Run by

Kadmon Corporation, LLC

People needed

41

Starts

2007-05-01

Expected to finish

2010-02-01

Last updated by the study team

2022-05-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed diagnosis of unresectable Stage IIIB or Stage IV relapsed or recurrent NSCLC.
• Subjects must have:
• documented (radiological or clinical) progressive disease (PD) following a prior response (including stable disease) to monotherapy with erlotinib or gefitinib that was administered for at least 12 weeks prior to progression OR
• a documented T790M EGFR mutation
• Measurable disease defined according to RECIST
• ECOG performance status of 0 or 1.
• Sexually active subjects must use an accepted method of contraception during the course of the study.
• Female subjects of childbearing potential must have a negative pregnancy test at enrollment.

You may not qualify if…

• Received radiation to ≥25% of his or her bone marrow within 30 days of XL647 treatment.
• Received erlotinib or gefitinib, or other anticancer therapy within 14 days of the first dose of study drug.
• Received an investigational drug (excluding erlotinib or gefitinib) within 30 days of the first dose of study drug.
• Receiving anticoagulation therapy with warfarin.
• Not recovered to Grade ≤1 from adverse events (AEs) due to antineoplastic agents, investigational drugs, or other medications that were administered prior to study enrollment.
• Corrected QT interval (QTc) of >0.45 seconds.
• Progressive, symptomatic, or hemorrhagic brain or leptomeningeal metastases.
• Requires steroid or anticonvulsant therapy for the treatment of brain metastases.

Where it is running

• Ronald Yanagihara — Gilroy, California, United States
• University of California Davis Cancer Center — Sacramento, California, United States
• Oncology Division and General Clincial Research, Stanford University Medical Center — Stanford, California, United States
• Cancer Care Center, Inc. P.C. — New Albany, Indiana, United States
• Washington County Hospital, The Center for Clinical Research — Hagerstown, Maryland, United States
• Wayne State University, Wertz Clinical Cancer Center, Karmanos Center — Detroit, Michigan, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• New Bern Cancer Care Oncology — New Bern, North Carolina, United States
• Case Western Reserve University, University Hospitals of Cleveland — Cleveland, Ohio, United States
• Signal Point Clinical Research Center — Middletown, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.